%PDF-1.4
%
60 0 obj
<>
endobj
57 0 obj
<>
endobj
121 0 obj
<>stream
Acrobat Distiller 4.05 for Macintosh
2004-11-29T18:44:47Z
2024-03-28T13:32:15-07:00
QuarkXPressª: AdobePS 8.6 (219)
2024-03-28T13:32:15-07:00
application/pdf
Heather
991307.nov
uuid:b7d4076e-1dd1-11b2-0a00-8f0827bd3700
uuid:b7d40771-1dd1-11b2-0a00-5b0000000000
endstream
endobj
46 0 obj
<>
endobj
47 0 obj
<>
endobj
61 0 obj
<>/ExtGState<>/Font<>/ProcSet[/PDF/Text]>>/Rotate 0/Type/Page>>
endobj
1 0 obj
<>/ExtGState<>/Font<>/ProcSet[/PDF/Text]>>/Rotate 0/Type/Page>>
endobj
4 0 obj
<>/ExtGState<>/Font<>/ProcSet[/PDF/Text]/XObject<>>>/Rotate 0/Type/Page>>
endobj
17 0 obj
<>/ExtGState<>/Font<>/ProcSet[/PDF/Text]/XObject<>>>/Rotate 0/Type/Page>>
endobj
25 0 obj
<>/ExtGState<>/Font<>/ProcSet[/PDF/Text]>>/Rotate 0/Type/Page>>
endobj
28 0 obj
<>/ExtGState<>/Font<>/ProcSet[/PDF/Text]>>/Rotate 0/Type/Page>>
endobj
31 0 obj
<>/ExtGState<>/Font<>/ProcSet[/PDF/Text]>>/Rotate 0/Type/Page>>
endobj
34 0 obj
<>/ExtGState<>/Font<>/ProcSet[/PDF/Text]>>/Rotate 0/Type/Page>>
endobj
151 0 obj
[155 0 R]
endobj
152 0 obj
<>stream
1 g
/GS0 gs
0 792 m
0 792 l
f
q
-1 793 614 -794 re
W n
q
0 792.06 612 -792 re
W n
BT
/CS0 cs 0 0 0 1 scn
/GS1 gs
/TT0 1 Tf
0.02499 Tw 8 0 0 8 74.4 714.5293 Tm
(guidelines. Guidelines for the management of rheumatoid arthritis.)Tj
0 -1.25 TD
(Arthritis Rheum 1996;39:713-22.)Tj
-2.175 -1.25 Td
[(12. )-600 (American College of Rheumatology ad hoc committee on clinical)]TJ
2.175 -1.25 Td
(guidelines. Guidelines for monitoring drug therapy in rheumatoid)Tj
T*
[(arthritis. )54.9 (Arthritis Rheum 1996;39:723-31.)]TJ
-0.00011 Tc -2.175 -1.25 Td
[(13. )-600.1 (Criswell LA, Such CL, )36.8 (Y)100 (elin EH. Dif)17.7 (ferences in the use of second-)]TJ
0 Tc 2.175 -1.25 Td
(line agents and prednisone for treatment of rheumatoid arthritis by)Tj
T*
(rheumatologists and non-rheumatologists. J Rheumatol)Tj
0 Tw T*
(1997;24:2283-90.)Tj
-0.00011 Tc 0.02499 Tw -2.175 -1.25 Td
[(14. )-600.1 (Blaauw )54.8 (AA, Schuwirth L)73.9 (W)91.7 (, van der )17.7 (Vleuten CP)110.7 (, Smits F)79.7 (,)-0.1 ( van der)]TJ
0 Tc 2.175 -1.25 Td
[(Linden S. )54.9 (Assessing clinical competence: recognition of case)]TJ
-0.00011 Tc T*
(descriptions of rheumatic diseases by general practitioners. Br J)Tj
0 Tc T*
(Rheumatol 1995;34:375-9.)Tj
-2.175 -1.25 Td
[(15. )-600 (Stross JK. Relationships between knowledge and experience in the)]TJ
-0.00011 Tc 2.175 -1.25 Td
(use of disease-modifying antirheumatic agents. JAMA)Tj
0 Tc 0 Tw T*
(1989;262:2721-3.)Tj
-0.00011 Tc 0.02499 Tw -2.175 -1.25 Td
[(16. )-600.1 (Mazzuca SA, Brandt KD, Katz BP)110.7 (, Li )17.7 (W)91.7 (, Steward KD. )17.7 (Therapeutic)]TJ
0 Tc 2.175 -1.25 Td
(strategies distinguish community-based primary care physicians)Tj
T*
(from rheumatologists in the management of osteoarthritis. )Tj
T*
(J Rheumatol 1993;20:80-6.)Tj
-0.00011 Tc -2.175 -1.25 Td
[(17. )-600.1 (Raspe HH, Mau )17.7 (W)91.7 (,)-0.1 ( )17.7 (W)79.7 (asmus )54.8 (A. )17.7 (T)34.8 (reatment profiles in dif)17.7 (ferent)]TJ
2.175 -1.25 Td
[(groups of RA-suf)17.7 (ferers: Description, analysis, evaluation. Scand J)]TJ
0 Tc T*
(Rheumatol 1989; 79 Suppl:57-65.)Tj
-2.175 -1.25 Td
[(18. )-600.1 (W)79.8 (ard MM. )17.7 (T)34.9 (rends in the use of disease modifying antirheumatic)]TJ
2.175 -1.25 Td
(medications in rheumatoid arthritis, 1980-1995: results from the)Tj
T*
[(National )54.9 (Ambulatory Medical Care Surveys. J Rheumatol)]TJ
0 Tw T*
(1999;26:546-50.)Tj
0.0249 Tw -2.175 -1.25 Td
[(19. )-600.1 (Kay EA, Pullar )17.7 (T)74 (. )17.7 (V)111.1 (ariations among rheumatologists in prescribing)]TJ
2.175 -1.25 Td
(and monitoring of disease modifying antirheumatoid drugs. Br J)Tj
T*
(Rheumatol 1992;31:477-83.)Tj
-2.175 -1.25 Td
[(20. )-600 (Henke CJ, Epstein )17.8 (WV)128.9 (. Practice variation in rheumatologists\222)]TJ
2.175 -1.25 Td
(encounters with their patients who have rheumatoid arthritis. Med)Tj
T*
(Care 1991;29:799-812.)Tj
-2.175 -1.25 Td
[(21. )-600 (Pincus )17.8 (T)74 (, Marcum SB, Callahan LF)79.8 (, et al. Longterm drug therapy)]TJ
2.175 -1.25 Td
(for rheumatoid arthritis in seven rheumatology private practices: I.)Tj
T*
(Nonsteroidal antiinflammatory drugs. J Rheumatol 1992;)Tj
0 Tw T*
(19:1874-84.)Tj
0.02499 Tw -2.175 -1.25 Td
[(22. )-600 (Pincus )17.8 (T)74 (, Marcum SB, Callahan LF)79.8 (. Longterm drug therapy for)]TJ
2.175 -1.25 Td
(rheumatoid arthritis in seven rheumatology private practices: II.)Tj
T*
(Second line drugs and prednisone. J Rheumatol 1992;19:1885-94.)Tj
-2.175 -1.25 Td
[(23. )-600.1 (Liang MH. )17.7 (The study of practice variation in managing rheumatic)]TJ
2.175 -1.25 Td
(diseases. Bull Rheum Dis 1994;43:6-8.)Tj
-2.175 -1.25 Td
[(24. )-600.1 (Zink )54.8 (A, Braun J, Listing J )17.7 (WJ. Disability and handicap in)]TJ
2.175 -1.25 Td
(rheumatoid arthritis and ankylosing spondylitis - results from the)Tj
T*
(German rheumatological database. J Rheumatol 2000;27:613-22.)Tj
-0.00011 Tc -2.175 -1.25 Td
[(25. )-600.1 (Zink )54.8 (A, Listing J, Klindworth C, Zeidler H for the German)]TJ
0 Tc 2.175 -1.25 Td
[(Collaborative )54.8 (Arthritis Centres. )17.7 (The National Database of the)]TJ
-0.00011 Tc 33 57.5 Td
[(German Collaborative )54.8 (Arthritis Centres. Structure, aims, and)]TJ
0 Tc T*
[(patients. )54.9 (Ann Rheum Dis 2001;60:199-206.)]TJ
-0.00011 Tc -2.175 -1.25 Td
[(26.)-875.1 (Zink )54.8 (A, Listing J, Niewerth M, Zeidler H for the German)]TJ
0 Tc 2.175 -1.25 Td
[(Collaborative )54.8 (Arthritis Centres. )17.7 (The National Database of the)]TJ
T*
[(German Collaborative )54.8 (Arthritis Centres. II. )17.7 (T)34.9 (reatment of patients)]TJ
T*
[(with rheumatoid arthritis. )54.9 (Ann Rheum Dis 2001;60:207-13.)]TJ
-0.00011 Tc -2.175 -1.25 Td
[(27. )-600.1 (Arnett FC, Edworthy SM, Bloch DA)-220.2 (MD, et al. )17.7 (The )54.8 (American)]TJ
2.175 -1.25 Td
[(Rheumatism )54.8 (Association 1987 revised criteria for the classification)]TJ
0 Tc T*
[(of rheumatoid arthritis. )54.8 (Arthritis Rheum 1988;31:315-24.)]TJ
-2.175 -1.25 Td
[(28. )-600 (Lautenschlaeger J, Mau )17.8 (W)91.8 (, Kohlmann )17.8 (T)74 (, et al. Comparative)]TJ
2.175 -1.25 Td
[(evaluation of a German version of the Health )54.9 (Assessment)]TJ
-0.00011 Tc T*
(Questionnaire \(HAQ\) and the Hanover Functional Status)Tj
0 Tc T*
[(Questionnaire \(HFSQ\). [V)110.8 (er)17.8 (gleichende Evaluation einer deutschen)]TJ
-0.00011 Tc T*
[(V)111 (ersion des Health )54.8 (Assessment Questionnaires \(HAQ\) und des)]TJ
T*
(Funktionsfragebogens Hannover \(FFbH\)]. Z Rheumatol 1997;)Tj
0 Tc 0 Tw T*
(144-55.)Tj
-0.00011 Tc 0.0249 Tw -2.175 -1.25 Td
[(29. )-600.2 (Norusis MJ. SPSS )54.7 (Advanced Statistics 6.1. Chicago \(SPSS)]TJ
0 Tw 2.175 -1.25 Td
(Inc.\)1994.)Tj
0 Tc 0.0249 Tw -2.175 -1.25 Td
[(30. )-600.1 (Galindo-Rodriguez G, )54.8 (A)74.2 (vina-Zubieta JA, Fitzgerald )54.8 (A, LeClerq SA,)]TJ
-0.00011 Tc 2.175 -1.25 Td
[(Russell )54.8 (AS, Suarez-Almazor ME. )17.7 (V)111 (ariations and trends in the)]TJ
0 Tc T*
(prescription of initial second line therapy for patients with)Tj
T*
(rheumatoid arthritis. J Rheumatol 1997;24:633-8.)Tj
-0.00011 Tc -2.175 -1.25 Td
[(31. )-600.2 (Suarez-Almazor ME, Soskolne CL, Saunders LD, Russell )54.7 (AS. Use)]TJ
0 Tc 2.175 -1.25 Td
(of second line drugs for the treatment of rheumatoid arthritis in)Tj
-0.00011 Tc T*
[(Edmonton, )54.8 (Alberta. Patterns of prescription and longterm)]TJ
0 Tc T*
[(ef)17.8 (fectiveness. J Rheumatol 1995;22:836-43.)]TJ
-0.00011 Tc -2.175 -1.25 Td
[(32. )-600.1 (Maetzel )54.8 (A, Bombardier C, Strand )17.7 (V)129.1 (,)-0.1 ( )17.7 (T)34.8 (ugwell P)110.7 (,)-0.1 ( )17.7 (W)79.7 (ells G. How)]TJ
0 Tc 2.175 -1.25 Td
(Canadian and US rheumatologists treat moderate or aggressive)Tj
T*
[(rheumatoid arthritis: a survey)64.9 (. J Rheumatol 1998;25:2331-8.)]TJ
-2.175 -1.25 Td
[(33. )-600.1 (Criswell LA, Redfearn )17.7 (WJ. )17.7 (V)111.1 (ariation among rheumatologists in the)]TJ
2.175 -1.25 Td
(use of prednisone and second-line agents for the treatment of)Tj
T*
[(rheumatoid arthritis. )54.9 (Arthritis Rheum 1994;37:476-80.)]TJ
-2.175 -1.25 Td
[(34. )-600 (Seichert N, Senn E. Electrotherapy in the rheumatic diseases.)]TJ
2.175 -1.25 Td
[([Elektrotherapie bei rheumatischen Erkrankungen]. )54.8 (Arthritis Rheum)]TJ
0 Tw T*
(1999;19:90-6.)Tj
0.0249 Tw -2.175 -1.25 Td
[(35. )-600.1 (Rush PJ, Shore )54.8 (A. Physician perceptions of the value of physical)]TJ
2.175 -1.25 Td
(modalities in the treatment of musculoskeletal disease. Br J)Tj
T*
(Rheumatol 1994;33:566-8.)Tj
-2.175 -1.25 Td
[(36. )-600.1 (W)79.8 (ard MM, Fries JF)79.8 (. )17.7 (T)34.9 (rends in antirheumatic medication use among)]TJ
2.175 -1.25 Td
(patients with rheumatoid arthritis, 1981-1996. J Rheumatol)Tj
0 Tw T*
(1998;25:408-16.)Tj
0.0249 Tw -2.175 -1.25 Td
[(37. )-600.1 (Criswell LA, Henke CJ. )17.7 (What explains the variation among)]TJ
2.175 -1.25 Td
(rheumatologists in their use of prednisone and second line agents)Tj
T*
(for the treatment of rheumatoid arthritis? J Rheumatol)Tj
0 Tw T*
(1995;22:829-35.)Tj
ET
/CS0 CS 0 0 0 1 SCN
54 54 m
558 54 l
S
BT
/TT1 1 Tf
0.02499 Tw 8 0 0 8 420.3613 35.9844 Tm
(The Journal of Rheumatology 2001; 28:10)Tj
0 Tw -45.7952 -0.0313 Td
(2208)Tj
ET
0 0 0 0 scn
/GS0 gs
102.3 58.39 407.5 -10.83 re
f*
0.5 w
102.3 58.39 407.5 -10.83 re
S
Q
Q
q
0 0 612 792 re
W n
BT
0 g
/GS2 gs
/T1_0 8 Tf
120.092 51 Td
(Personal non-commercial use only. The Journal of Rheumatology Copyright\
\251 2001. All rights reserved.)Tj
ET
Q
BT
0 g
/GS2 gs
/T1_1 1 Tf
10 0 0 10 540 17 Tm
( )Tj
0 0.48627 0.77255 rg
/GS2 gs
-7.22298 0 Td
(www.jrheum.org)Tj
0 g
/GS2 gs
-16.72996 0 Td
(Downloaded on March 28, 2024 from )Tj
ET
endstream
endobj
104 0 obj
<>
endobj
126 0 obj
<>
endobj
69 0 obj
<>
endobj
65 0 obj
<>
endobj
63 0 obj
<>
endobj
98 0 obj
<>stream
HV pUBBr@6d7!$ñ\ LcD0 TJ@(tXpqYXDդ-
( ZR@T,DX`zKo@@AzMPS: